公开(公告)号：US20170306014A1

公开(公告)日：2017-10-26

申请号：US15509859

申请日：2015-09-09

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395

CPC classification number: C07K16/2803 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76

Abstract: This invention relates to agents that bind multiple Siglecs, including antibodies that neutralize the inhibitory activity of multiple Siglec-7 and Siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US20170298131A1

公开(公告)日：2017-10-19

申请号：US15511792

申请日：2015-09-15

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US09708403B2

公开(公告)日：2017-07-18

申请号：US14665731

申请日：2015-03-23

Applicant: Novo Nordisk A/S ,  Innate Pharma

Inventor： Søren Berg Padkær ,  Peter Andreas Nicolai Reumert Wagtmann ,  Petrus Johannes Louis Spee ,  Stefan Zahn ,  Kristian Kjærgaard ,  Anders Svensson

IPC: C12P21/04 ,  C07H21/00 ,  C12P15/00 ,  C12N15/00 ,  C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/28 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76

Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

公开(公告)号：US20170198038A1

公开(公告)日：2017-07-13

申请号：US15321650

申请日：2015-06-23

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Nadia ANCERIZ ,  Ariane MOREL ,  Benjamin ROSSI

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/71 ,  C07K2317/92 ,  C07K2319/30

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20160046712A1

公开(公告)日：2016-02-18

申请号：US14665731

申请日：2015-03-23

Applicant: Novo Nordisk A/S - Novo Allé ,  Innate Pharma S.A.S.

Inventor： Søren Berg Padkær ,  Peter Andreas, Nicolai, Reumert Wagtmann ,  Pieter Spee ,  Stefan Zahn ,  Kristian Kjærgaard ,  Anders Svensson

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/28 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76

Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

Abstract translation: 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负信号可涉及配体结合诱导的KIR分子的构象重构，允许在特定结构域中的相邻KIR之间形成相互作用，导致加速 聚类 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来降低或阻断HLA结合。

公开(公告)号：US20150299319A1

公开(公告)日：2015-10-22

申请号：US14789548

申请日：2015-07-01

Applicant: INNATE PHARMA S.A.

Inventor： Andrea Velardi ,  Francois Romagne

IPC: C07K16/28 ,  G01N33/50

CPC classification number: C07K16/2803 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2887 ,  C07K16/2893 ,  C07K16/2896 ,  C07K2317/732 ,  C07K2317/76 ,  C12N5/0646 ,  G01N33/5047 ,  G01N2333/70535 ,  G01N2500/10

Abstract: The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.

Abstract translation: 本发明一般涉及提高治疗性抗体效率的方法和组合物。 通过增加ADCC机制，提高效率。 更具体地说，本发明涉及治疗性抗体与阻断NK细胞的抑制性受体或刺激NK细胞活化受体的化合物的组合的用途，以增强人受试者用治疗性抗体治疗的效率。

公开(公告)号：US20150291692A1

公开(公告)日：2015-10-15

申请号：US14429416

申请日：2013-09-17

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  BENJAMIN ROSSI ,  HÉLÈNE SICARD ,  CARINE PATUREL

IPC: C07K16/28 ,  G01N33/569 ,  A61K47/48

CPC classification number: C07K16/2803 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/56972 ,  G01N2333/70503 ,  G01N2800/24 ,  G01N2800/52 ,  G01N2800/7028 ,  G01N2800/7095

Abstract: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy, to a method of selecting an appropriate chemotherapeutic treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one of a soluble B7H6 (sB7H6 or sB7-H6) and a soluble MIC (sMIC) and when the expression level is determined a step b) of comparing said expression level to a reference expression level, thereby assessing or monitoring whether the subject having a tumor is responsive or resistant to the chemotherapy.

Abstract translation: 本发明涉及一种预测或监测具有肿瘤的受试者对化疗的敏感性的方法，选择适合的癌症化学治疗的方法，筛选或鉴定适于改善治疗的化合物的方法 癌症，以及相应的药盒。 预测或监测具有肿瘤的受试者对化疗的敏感性的方法通常包括以下步骤：a）在来自所述受试者的生物样品中测定可溶性B7H6中的至少一种的存在，不存在或表达水平（ sB7H6或sB7-H6）和可溶性MIC（sMIC），并且当确定表达水平时，将所述表达水平与参考表达水平进行比较的步骤b），从而评估或监测具有肿瘤的受试者是否具有反应性或抗性 化疗。

公开(公告)号：US20150232556A1

公开(公告)日：2015-08-20

申请号：US14662349

申请日：2015-03-19

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  SIMON KOLLNBERGER ,  BENJAMIN ROSSI ,  HÉLÈNE SICARD ,  CARINE PATUREL ,  STÉPHANIE CORNEN ,  STÉPHANIE ZERBIB

IPC: C07K16/28 ,  G01N33/569

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

Abstract translation: 本发明涉及使用特异性结合KIR3DL2的抗体（例如单克隆抗体），抗体片段及其衍生物来治疗癌症和炎性疾病的方法。 本发明还涉及抗体，产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 含有该组合物的药物组合物。

公开(公告)号：US20150125464A1

公开(公告)日：2015-05-07

申请号：US14594353

申请日：2015-01-12

Applicant: Innate Pharma, S.A. ,  University of Genova

Inventor： ALESSANDRO MORETTA ,  EMANUELA MARCENARO ,  FRANCOIS ROMAGNE ,  PASCALE ANDRE

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/572 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/76 ,  G01N33/56966 ,  G01N2333/70596 ,  G01N2500/04

Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

公开(公告)号：US20140023646A1

公开(公告)日：2014-01-23

申请号：US14043402

申请日：2013-10-01

Applicant: Innate Pharma S.A.S. ,  Novo Norkish A/S

Inventor： Peter Andreas, Nicolai, Reumert WAGTMANN ,  Francois ROMAGNE ,  Joakim GLAMANN

IPC: A61K39/395 ,  A61K45/06

CPC classification number: A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/08 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.

Abstract translation: 描述了使用阻断抑制性NK细胞受体的化合物治疗病毒性疾病的方法，从而降低其在杀死感染的靶细胞中NK细胞的细胞毒性的抑制。 在一个实施方案中，所述化合物是结合例如人KIR2DL1，KIR2DL2和KIR2DL3受体中的一种或多种的抗体。 在另一个实施方案中，所述方法还包括施用结合感染病毒的细胞上表达的抗原的治疗性抗体或融合蛋白。